Quality Investor
About 

Crane NXT, Co.

Rank #361Value

CXT · NYSE · Industrials

Crane NXT, Co. (CXT) — Rank #361 by gross profitability (GP/assets 0.20) · ROE 11.5% · Piotroski F-Score 5 / 9.

As-of 2026-09-15 · CIK 0000025445 · all metrics point-in-time as of the filing date.

About

Crane NXT, Co. operates as an industrial technology company that provides technology solutions to secure, detect, and authenticate customers' important assets.

Show more

The company operates through Crane Payment Innovations; and Security and Authentication Technologies segments. The Crane Payment Innovations segment offers electronic equipment and associated software, as well as advanced automation solutions, processing systems, field service solutions, remote diagnostics, and productivity software solutions. The Security and Authentication Technologies segment provides advanced security solutions based on proprietary technology for securing physical products, including banknotes, consumer goods, and industrial products. This segment also offers brand protection, authentication solutions, and digital content protection across online marketplaces, social media platforms, and websites; and serves various brands, as well as government agencies and financial institutions. Crane NXT, Co.

was incorporated in 2021 and is based in Waltham, Massachusetts.

Industry
Business Equipment & Supplies
Sector
Industrials
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
December 31

Price History

CXT+65.0% · +10.5% CAGRSPY+80.5% · +12.5% CAGR

Company Snapshot

P/E and dividend yield are the primary valuation lenses for mature businesses.

Market Cap

$2.76B

P/E (annual)

19.2

P/S (annual)

1.7

P/B

2.2

P/OCF (annual)

11.4

Shareholder Yield

-0.9%

Employees

4,800

Industry

Business Equipment & Supplies

Exchange

NYSE

Signal Flags

2 green2 yellow3 red
Operating leverage expandingOperating income growing faster than revenue
Sequential beat (rev + EPS)Both revenue and EPS exceeded prior quarter — 2-quarter streak
Dilution above 2%Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation
Disclosure regressionA previously-disclosed line item is no longer reported — worth checking the filing for why
Revenue declining YoYRevenue contracted year over year
Balance sheet deterioratingNet cash collapsed with receivables or inventory outpacing revenue
Valuation convergenceEPS declining, shares diluting, and revenue growth decelerating simultaneously

Quality Profile

Profitability

1/1 pass
GP / assets
0.20
Return on equity
11.5%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
1.83
Current ratio
1.42×
Net cash
-$1.22B

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
0.8%

Growth

0/2 pass
Revenue growth
-51.4%
Piotroski F-Score
5 / 9
Share dilution
2.3%

Terry Smith quality gate

Passes 1/5 Terry Smith thresholds

1 of 5 threshold not computable from filed data.

What Growth Is Priced In

Implied revenue growth (10Y)

2.9%

incredible deal

The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).

Dilution drag: 2.3% — per-share value needs a total required return of 5.2% once share-count change is priced in.

vs. own 6-year median revenue growth: 7.1%

within its own history

Cost-of-equity sensitivity (implied growth at different discount rates)

r = 8%

-1.1%

r = 10% (base)

2.9%

r = 12%

6.4%

Net debt / market cap: 43.9%— material leverage inflates the implied growth read.

Base FCF: $198.3M3Y mean FCF: $160.1M

Valuation History

Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.

P / E

Price / diluted EPS

6.0xCheap
4.8xmed 7.3x14.3x

P / S

Price / revenue per share

0.7xExpensive
0.4xmed 0.6x0.7x

P / B

Price / book value per share

1.3xFair
1.0xmed 1.2x1.5x

P / GP

Price / gross profit per share

1.8xExpensive
1.2xmed 1.6x1.8x

P / FCF

Price / free cash flow per share

N/A
5.0xmed 6.4x8.7x

Dividend yield and payout ratio are the primary reads at this stage (trailing P/E — see valuation above).

Profitability

Gross profitability (GP / assets)

0.20

Primary signal (Novy-Marx).

5th of 5 SIC 3490 peers

Return on equity

11.5%

Gross margin

42.5%

2nd of 5 SIC 3490 peers

Revenue growth (YoY)

-51.4%

RPO growth (YoY)

-60.8%

Remaining performance obligations growth — RPO > revenue = forward demand building.

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2019202020212022
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

Earnings CAGR (3Y)

-10.9%

FCF CAGR (3Y)

—

Anti-fragile safety

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

1.83

5th of 5 SIC 3490 peers (best = lowest)

Current ratio

1.42×

4th of 5 SIC 3490 peers

Quick ratio

0.92×

Net cash

-$1.22B

Cash & equivalents minus total debt.

Cash-flow health

Free cash flow

$198.30M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF / net income

0.37

Cash-backing of earnings.

FCF/NI divergence

Unfavorable divergence (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

0.8%

Stock-based comp intensity.

Dividend safety

Composite score

3.0 / 5

Good
Payout ratio
26.9%5/5 Strong
FCF coverage
5.08×5/5 Strong
Dividend growth streak
2 yr1/5 Weak
Balance-sheet health
D/E 1.83 · IC N/A1/5 Weak

Piotroski F-Score

F-Score

5 / 9

Fundamental-strength score (0-9).

Lifecycle Phase History

20172022
Op. Leverage
Value
Capital Return
View full financial statements →